Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein/beta2-glycoprotein i complex concentration in type 2 diabetes

Paul Rj Ames, Alfredo Ortiz-Cadenas, Ignacio Garcia-De La Torre, Arnulfo Nava, Aldo Oregon-Miranda, Joana R. Batuca, Kazuo Kojima, Luis R. Lopez, Eiji Matsuura

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aims To evaluate the effect of rosuvastatin on oxidised low-density lipoprotein/beta2-glycoprotein I (oxLDL/ β2GPI) complex concentration in type 2 diabetes mellitus. Methods: open label 2:1 assignment of consecutive diabetic patients into oral rosuvastatin (10 mg daily for six weeks) arm or observational arm with measurements of serum oxLDL/ β2GPI complexes, nitric oxide metabolites, asymmetric dimethyl arginine, nitrotyrosine alongside routine biochemistry at baseline and end of study in all patients. Results After rosuvastatin treatment the mean serum concentration of oxLDL/β2GPI decreased from 0.79±0.49 units/mL to 0.53±0.36 units/mL (p2GPI complexes, which is in further support of the already proposed effects of the drug on the oxidative metabolism of lipids and/or LDL. The oxLDL/β2GPI complex may represent a surrogate marker of oxidative stress in type 2 diabetes.

Original languageEnglish
Pages (from-to)292-299
Number of pages8
JournalBritish Journal of Diabetes and Vascular Disease
Volume10
Issue number6
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Type 2 Diabetes Mellitus
Glycoproteins
beta 2-Glycoprotein I
Serum
Therapeutics
Biochemistry
Arginine
Nitric Oxide
Oxidative Stress
Biomarkers
Rosuvastatin Calcium
oxidized low density lipoprotein
Lipids

Keywords

  • diabetes
  • oxidative stress
  • oxidised low-density lipoprotein/beta2- glycoprotein I

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein/beta2-glycoprotein i complex concentration in type 2 diabetes. / Ames, Paul Rj; Ortiz-Cadenas, Alfredo; Garcia-De La Torre, Ignacio; Nava, Arnulfo; Oregon-Miranda, Aldo; Batuca, Joana R.; Kojima, Kazuo; Lopez, Luis R.; Matsuura, Eiji.

In: British Journal of Diabetes and Vascular Disease, Vol. 10, No. 6, 11.2010, p. 292-299.

Research output: Contribution to journalArticle

Ames, Paul Rj ; Ortiz-Cadenas, Alfredo ; Garcia-De La Torre, Ignacio ; Nava, Arnulfo ; Oregon-Miranda, Aldo ; Batuca, Joana R. ; Kojima, Kazuo ; Lopez, Luis R. ; Matsuura, Eiji. / Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein/beta2-glycoprotein i complex concentration in type 2 diabetes. In: British Journal of Diabetes and Vascular Disease. 2010 ; Vol. 10, No. 6. pp. 292-299.
@article{e8ab807d84e14f39b86d48a497638a73,
title = "Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein/beta2-glycoprotein i complex concentration in type 2 diabetes",
abstract = "Aims To evaluate the effect of rosuvastatin on oxidised low-density lipoprotein/beta2-glycoprotein I (oxLDL/ β2GPI) complex concentration in type 2 diabetes mellitus. Methods: open label 2:1 assignment of consecutive diabetic patients into oral rosuvastatin (10 mg daily for six weeks) arm or observational arm with measurements of serum oxLDL/ β2GPI complexes, nitric oxide metabolites, asymmetric dimethyl arginine, nitrotyrosine alongside routine biochemistry at baseline and end of study in all patients. Results After rosuvastatin treatment the mean serum concentration of oxLDL/β2GPI decreased from 0.79±0.49 units/mL to 0.53±0.36 units/mL (p2GPI complexes, which is in further support of the already proposed effects of the drug on the oxidative metabolism of lipids and/or LDL. The oxLDL/β2GPI complex may represent a surrogate marker of oxidative stress in type 2 diabetes.",
keywords = "diabetes, oxidative stress, oxidised low-density lipoprotein/beta2- glycoprotein I",
author = "Ames, {Paul Rj} and Alfredo Ortiz-Cadenas and {Garcia-De La Torre}, Ignacio and Arnulfo Nava and Aldo Oregon-Miranda and Batuca, {Joana R.} and Kazuo Kojima and Lopez, {Luis R.} and Eiji Matsuura",
year = "2010",
month = "11",
doi = "10.1177/1474651410388057",
language = "English",
volume = "10",
pages = "292--299",
journal = "British Journal of Diabetes and Vascular Disease",
issn = "1474-6514",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein/beta2-glycoprotein i complex concentration in type 2 diabetes

AU - Ames, Paul Rj

AU - Ortiz-Cadenas, Alfredo

AU - Garcia-De La Torre, Ignacio

AU - Nava, Arnulfo

AU - Oregon-Miranda, Aldo

AU - Batuca, Joana R.

AU - Kojima, Kazuo

AU - Lopez, Luis R.

AU - Matsuura, Eiji

PY - 2010/11

Y1 - 2010/11

N2 - Aims To evaluate the effect of rosuvastatin on oxidised low-density lipoprotein/beta2-glycoprotein I (oxLDL/ β2GPI) complex concentration in type 2 diabetes mellitus. Methods: open label 2:1 assignment of consecutive diabetic patients into oral rosuvastatin (10 mg daily for six weeks) arm or observational arm with measurements of serum oxLDL/ β2GPI complexes, nitric oxide metabolites, asymmetric dimethyl arginine, nitrotyrosine alongside routine biochemistry at baseline and end of study in all patients. Results After rosuvastatin treatment the mean serum concentration of oxLDL/β2GPI decreased from 0.79±0.49 units/mL to 0.53±0.36 units/mL (p2GPI complexes, which is in further support of the already proposed effects of the drug on the oxidative metabolism of lipids and/or LDL. The oxLDL/β2GPI complex may represent a surrogate marker of oxidative stress in type 2 diabetes.

AB - Aims To evaluate the effect of rosuvastatin on oxidised low-density lipoprotein/beta2-glycoprotein I (oxLDL/ β2GPI) complex concentration in type 2 diabetes mellitus. Methods: open label 2:1 assignment of consecutive diabetic patients into oral rosuvastatin (10 mg daily for six weeks) arm or observational arm with measurements of serum oxLDL/ β2GPI complexes, nitric oxide metabolites, asymmetric dimethyl arginine, nitrotyrosine alongside routine biochemistry at baseline and end of study in all patients. Results After rosuvastatin treatment the mean serum concentration of oxLDL/β2GPI decreased from 0.79±0.49 units/mL to 0.53±0.36 units/mL (p2GPI complexes, which is in further support of the already proposed effects of the drug on the oxidative metabolism of lipids and/or LDL. The oxLDL/β2GPI complex may represent a surrogate marker of oxidative stress in type 2 diabetes.

KW - diabetes

KW - oxidative stress

KW - oxidised low-density lipoprotein/beta2- glycoprotein I

UR - http://www.scopus.com/inward/record.url?scp=79751475968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79751475968&partnerID=8YFLogxK

U2 - 10.1177/1474651410388057

DO - 10.1177/1474651410388057

M3 - Article

VL - 10

SP - 292

EP - 299

JO - British Journal of Diabetes and Vascular Disease

JF - British Journal of Diabetes and Vascular Disease

SN - 1474-6514

IS - 6

ER -